Gil Wolfe, MD
Neurology · Buffalo, NYNPI 1215995535
Payments from drug & device makers
Across 699 payments — averaging $1185.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$248K
- Grifols USA, LLC$176K
- AstraZeneca$175K
- UCB, Inc.$47K
- Genentech, Inc.$46K
- Argenx US, Inc.$42K
- plus $95K from 28 others
Across 7 payments — averaging $568.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$2K
- Argenx US, Inc.$853
- Regeneron$377
- EMD Serono, Inc.$364
What the payments were for
- Consulting fees$265,69343%
- Speaking & faculty fees$258,09442%
- Travel & lodging$78,03013%
- Food & beverage$15,0072%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 39 | $247,879 |
| Grifols USA, LLC | 180 | $175,551 |
| AstraZeneca | 227 | $174,760 |
| UCB, Inc. | 77 | $46,745 |
| Genentech, Inc. | 5 | $46,466 |
| Argenx US, Inc. | 55 | $42,306 |
| Janssen Global Services, LLC | 26 | $30,994 |
| Johnson & Johnson | 15 | $15,328 |
| Amgen(2 entities) | 17 | $12,680 |
| UCB Biosciences Inc. | 4 | $10,428 |
| Shire North American Group Inc | 10 | $5,165 |
| Novartis | 3 | $4,157 |
| F. Hoffmann-la Roche AG | 3 | $3,435 |
| H. Lundbeck A S | 2 | $3,300 |
| Grifols Shared Services North America, Inc. | 3 | $2,355 |
| Sanofi-aventis U.S. LLC | 3 | $2,012 |
| Merck Kgaa | 1 | $1,240 |
| Janssen Research & Development, LLC | 1 | $625 |
| Samsung Bioepis Co., Ltd. | 1 | $600 |
| Vertex | 1 | $433 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $428 |
| CSL Behring | 4 | $406 |
| Sanofi | 3 | $256 |
| Biogen | 3 | $252 |
| Sarepta Therapeutics, Inc. | 3 | $179 |
| Janssen Scientific Affairs, LLC | 1 | $149 |
| TG Therapeutics, Inc. | 1 | $112 |
| Alnylam Pharmaceuticals Inc. | 1 | $106 |
| Boston Scientific | 1 | $100 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 1 | $100 |
| Regeneron | 1 | $66 |
| Genentech USA, Inc. | 3 | $43 |
| Catalyst Pharmaceuticals, Inc. | 1 | $27 |
| Upsher-smith Laboratories LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Gamunex-C$163,737
- ULTOMIRIS$71,395
- SOLIRIS$64,165
- VYVGART$27,422
- Rystiggo$20,351
- Xembify$12,378
- VYVGART HYTRULO$9,965
- Zilbrysq$9,892
- UPLIZNA$9,439
- Enspryng$5,586
- GAMMAGARD LIQUID$800
- Hizentra$381
- NEXVIAZYME$132
- SPINRAZA$115
- BRIUMVI$112
- WATCHMAN FLX$100
How this compares
$828,701 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pyridostigmine Bromide | 47 | $2,784 |
| Mycophenolate Mofetil | 24 | $2,072 |
| Gabapentin | 29 | $599 |
| Prednisone | 41 | $261 |
Paid to pharmacies, not to this prescriber.
Other neurology in Buffalo
- Kinga SzigetiBuffalo$3M
- Bianca Weinstock GuttmanBuffalo$1.4M
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Richard HolubAlbany$6.3M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
- Laszlo MechtlerAmherst$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.